TheraRadar
← Back
Data updated: Jun 28, 2026

ALPHARMA US PHARMS

Generics

ALPHARMA US PHARMS is a generic drug manufacturer focused on Dermatology, Respiratory.

1965
Since
43
Drugs
-
Trials
0
New Drugs (2yr)

ALPHARMA US PHARMS's Key Drugs

ALPHARMA US PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ALPHARMA US PHARMS's Recent FDA Approvals

New NDA/BLA approvals for ALPHARMA US PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALPHARMA US PHARMS's Therapeutic Areas

ALPHARMA US PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 67%
2 drugs
Respiratory 33%
1 drugs

ALPHARMA US PHARMS's Top Competitors

ALPHARMA US PHARMS's closest competitors by therapeutic-area and drug-target overlap include Bayer, APOTHECON, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ALPHARMA US PHARMS Pipeline Snapshot

Active clinical trials for ALPHARMA US PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling